REGULATORY

MHLW Expands Eligibility for “Specific-Use Drug” Designation

March 5, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan will expand the eligibility criteria for the designation of “drugs for specific use” to include new active ingredients and introduce a framework allowing pharmaceutical companies to request designation themselves from May. The Ministry of Health, Labor and Welfare (MHLW)…

To read the full story

MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025

REGULATORY

Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
MHLW Gives Kissei until July 21 to Report on Tavneos
July 3, 2026
Centrist Reform Alliance Warns US MFN Policy Poses “Real Crisis” for Drug Access
July 3, 2026
Ishin Urges Govt to Make Healthcare, Drug Innovation Core Growth Strategy
July 3, 2026
MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

COMMENTARY

New Generic Listings Plunge, Industry Heads for a Shakeout

By Tatsuya Otsuka

The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…